FOMX

Foamix Pharmaceuticals Ltd.CIK 1606645 ☆ Sign in to watch Congress trades

Open-mkt buys · 90d

—

0 trades · 0 insiders

Open-mkt sales · 90d

—

0 trades · 0 insiders

Net · 90d

Insiders on file

AI insights for FOMX PRO

XXXX	$█.██M	██	+██%
XXXX	$█.██M	██	+██%
XXXX	$█.██M	██	+██%
XXXX	$█.██M	██	+██%
XXXX	$█.██M	██	+██%

AI insights for FOMX

Insider sentiment score with a plain-English explanation, conviction score on every buy, and how the stock performed 30 and 90 days after past insider buys.

Upgrade to Pro · $99/year Already Pro? Log in

Daily buy vs sell · 90 days

No data yet.

Insiders

Insider	Role	Trades	Bought	Sold	Last trade
Wiley Matthew T.	Chief Commercial Officer	12	$50.5K	$0	2020-03-09
Hirsch Stanley	Director	20	$0	$31.4K	2020-03-09
Harsch Mutya	General Counsel and SVP	17	$0	$10.9K	2020-03-09
Domzalski David	CEO	35	$0	$113.9K	2020-03-09
Stuart Iain	SVP R&D	19	$0	$27.1K	2020-03-09
Hadar Ilan	CFO & Country Manager	24	$0	$153.3K	2020-03-09
Schwartz Aharon	Director	12	$437.8K	$0	2020-03-09
Bruno Anthony D	Director	4	$0	$0	2020-03-09
KAZANCHYAN ANNA	Director	10	$0	$52.6K	2020-03-09
Bright Rex	Director	8	$0	$0	2020-03-09
BARBARI SHARON SURREY	Director	2	$0	$0	2020-03-09
STERN STANLEY	Director	10	$0	$0	2020-03-09
Howard Alvin D	VP Regulatory	9	$0	$16.9K	2018-11-19
Elliott Russell P.	VP Drug Development	9	$0	$7.3K	2018-10-01
Megiddo Dalia	Director	1	$0	$0	2018-05-08
RIGEL DARRELL S	Director	1	$0	$0	2018-05-08
Shirvan Mitchell	VP Innovation & Discovery	6	$0	$0	2018-02-27
Schuz David	VP Intellectual Property	6	$0	$0	2018-02-27
Hazot Yohan	VP Pharmaceutical Development	6	$0	$0	2018-02-27
Eini Meir	Other	12	$0	$251.8K	2018-01-15

Trade history

Insider	Role	Code	Trade	Filed	Shares	Price	Value	Owned after
BARBARI SHARON SURREY	Director	D To issuer deriv	2020-03-09	2020-03-11	49,412	—	$0	0	SEC↗
Bright Rex	Director	D To issuer deriv	2020-03-09	2020-03-11	38,156	—	$0	0	SEC↗
Bright Rex	Director	D To issuer deriv	2020-03-09	2020-03-11	27,000	—	$0	0	SEC↗
Bright Rex	Director	D To issuer deriv	2020-03-09	2020-03-11	21,562	—	$0	0	SEC↗
Bright Rex	Director	D To issuer deriv	2020-03-09	2020-03-11	24,947	—	$0	0	SEC↗
Bright Rex	Director	D To issuer deriv	2020-03-09	2020-03-11	49,412	—	$0	0	SEC↗
Domzalski David	CEO	D To issuer deriv	2020-03-09	2020-03-11	18,750	—	$0	0	SEC↗
Domzalski David	CEO	D To issuer deriv	2020-03-09	2020-03-11	236,810	—	$0	0	SEC↗
Domzalski David	CEO	D To issuer deriv	2020-03-09	2020-03-11	70,187	—	$0	0	SEC↗
Domzalski David	CEO	D To issuer deriv	2020-03-09	2020-03-11	170,993	—	$0	0	SEC↗
Domzalski David	CEO	D To issuer deriv	2020-03-09	2020-03-11	240,912	—	$0	0	SEC↗
Domzalski David	CEO	D To issuer deriv	2020-03-09	2020-03-11	71,369	—	$0	0	SEC↗
Domzalski David	CEO	D To issuer deriv	2020-03-09	2020-03-11	327,720	—	$0	0	SEC↗
Domzalski David	CEO	D To issuer deriv	2020-03-09	2020-03-11	60,000	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer deriv	2020-03-09	2020-03-11	5,469	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer deriv	2020-03-09	2020-03-11	24,125	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer deriv	2020-03-09	2020-03-11	18,000	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer deriv	2020-03-09	2020-03-11	202,004	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer deriv	2020-03-09	2020-03-11	60,000	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer deriv	2020-03-09	2020-03-11	60,389	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer deriv	2020-03-09	2020-03-11	196,205	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer deriv	2020-03-09	2020-03-11	35,093	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer deriv	2020-03-09	2020-03-11	96,365	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer deriv	2020-03-09	2020-03-11	94,996	—	$0	0	SEC↗
Harsch Mutya	CLO and General Counsel	D To issuer deriv	2020-03-09	2020-03-11	50,000	—	$0	0	SEC↗
Harsch Mutya	CLO and General Counsel	D To issuer deriv	2020-03-09	2020-03-11	70,297	—	$0	0	SEC↗
Harsch Mutya	CLO and General Counsel	D To issuer deriv	2020-03-09	2020-03-11	96,365	—	$0	0	SEC↗
Hirsch Stanley	Director	D To issuer deriv	2020-03-09	2020-03-11	49,766	—	$0	0	SEC↗
Hirsch Stanley	Director	D To issuer deriv	2020-03-09	2020-03-11	27,000	—	$0	0	SEC↗
Hirsch Stanley	Director	D To issuer deriv	2020-03-09	2020-03-11	82,153	—	$0	0	SEC↗
KAZANCHYAN ANNA	Director	D To issuer deriv	2020-03-09	2020-03-11	3,000	—	$0	0	SEC↗
KAZANCHYAN ANNA	Director	D To issuer deriv	2020-03-09	2020-03-11	8,000	—	$0	0	SEC↗
Schwartz Aharon	Director	D To issuer deriv	2020-03-09	2020-03-11	24,883	—	$0	0	SEC↗
Schwartz Aharon	Director	D To issuer deriv	2020-03-09	2020-03-11	49,412	—	$0	0	SEC↗
Schwartz Aharon	Director	D To issuer deriv	2020-03-09	2020-03-11	38,156	—	$0	0	SEC↗
Schwartz Aharon	Director	D To issuer deriv	2020-03-09	2020-03-11	21,435	—	$0	0	SEC↗
Schwartz Aharon	Director	D To issuer deriv	2020-03-09	2020-03-11	24,000	—	$0	0	SEC↗
Stuart Iain	Chief Scientific Officer	D To issuer deriv	2020-03-09	2020-03-11	96,365	—	$0	0	SEC↗
Stuart Iain	Chief Scientific Officer	D To issuer deriv	2020-03-09	2020-03-11	40,000	—	$0	0	SEC↗
Stuart Iain	Chief Scientific Officer	D To issuer deriv	2020-03-09	2020-03-11	13,000	—	$0	0	SEC↗
Stuart Iain	Chief Scientific Officer	D To issuer deriv	2020-03-09	2020-03-11	30,000	—	$0	0	SEC↗
Stuart Iain	Chief Scientific Officer	D To issuer deriv	2020-03-09	2020-03-11	75,997	—	$0	0	SEC↗
Wiley Matthew T.	Chief Commercial Officer	D To issuer deriv	2020-03-09	2020-03-11	100,000	—	$0	0	SEC↗
Wiley Matthew T.	Chief Commercial Officer	D To issuer deriv	2020-03-09	2020-03-11	96,365	—	$0	0	SEC↗
STERN STANLEY	Director	D To issuer deriv	2020-03-09	2020-03-18	27,000	—	$0	0	SEC↗
STERN STANLEY	Director	D To issuer deriv	2020-03-09	2020-03-18	12,719	—	$0	0	SEC↗
STERN STANLEY	Director	D To issuer deriv	2020-03-09	2020-03-18	24,947	—	$0	0	SEC↗
STERN STANLEY	Director	D To issuer deriv	2020-03-09	2020-03-18	21,562	—	$0	0	SEC↗
Bruno Anthony D	Director	D To issuer	2020-03-09	2020-03-11	62,647	—	$0	12,360	SEC↗
Bruno Anthony D	Director	D To issuer	2020-03-09	2020-03-11	12,360	—	$0	0	SEC↗
Domzalski David	CEO	D To issuer	2020-03-09	2020-03-11	90,902	—	$0	233,126	SEC↗
Domzalski David	CEO	D To issuer	2020-03-09	2020-03-11	233,126	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer	2020-03-09	2020-03-11	14,077	—	$0	116,501	SEC↗
Hadar Ilan	CFO & Country Manager	D To issuer	2020-03-09	2020-03-11	116,501	—	$0	0	SEC↗
Harsch Mutya	CLO and General Counsel	D To issuer	2020-03-09	2020-03-11	85,490	—	$0	0	SEC↗
Harsch Mutya	CLO and General Counsel	D To issuer	2020-03-09	2020-03-11	12,742	—	$0	85,490	SEC↗
Hirsch Stanley	Director	D To issuer	2020-03-09	2020-03-11	52,842	—	$0	241,516	SEC↗
Hirsch Stanley	Director	D To issuer	2020-03-09	2020-03-11	59,016	—	$0	0	SEC↗
Hirsch Stanley	Director	D To issuer	2020-03-09	2020-03-11	182,500	—	$0	59,016	SEC↗
KAZANCHYAN ANNA	Director	D To issuer	2020-03-09	2020-03-11	15,714	—	$0	43,030	SEC↗
KAZANCHYAN ANNA	Director	D To issuer	2020-03-09	2020-03-11	43,030	—	$0	0	SEC↗
Schwartz Aharon	Director	D To issuer	2020-03-09	2020-03-11	112,200	—	$0	0	SEC↗
Stuart Iain	Chief Scientific Officer	D To issuer	2020-03-09	2020-03-11	91,303	—	$0	0	SEC↗
Stuart Iain	Chief Scientific Officer	D To issuer	2020-03-09	2020-03-11	12,333	—	$0	91,303	SEC↗
Wiley Matthew T.	Chief Commercial Officer	D To issuer	2020-03-09	2020-03-11	35,275	—	$0	78,799	SEC↗
Wiley Matthew T.	Chief Commercial Officer	D To issuer	2020-03-09	2020-03-11	78,799	—	$0	0	SEC↗
STERN STANLEY	Director	D To issuer	2020-03-09	2020-03-18	21,147	—	$0	21,212	SEC↗
STERN STANLEY	Director	D To issuer	2020-03-09	2020-03-18	21,212	—	$0	0	SEC↗
Domzalski David	CEO	A Award	2020-03-02	2020-03-03	4,705	$2.68	$12.6K	324,028	SEC↗
Harsch Mutya	CLO and General Counsel	A Award	2020-03-02	2020-03-03	1,761	$2.68	$4.7K	98,232	SEC↗
Wiley Matthew T.	Chief Commercial Officer	A Award	2020-03-02	2020-03-03	1,993	$2.68	$5.3K	114,074	SEC↗
Bright Rex	Director	A Award deriv	2020-02-27	2020-03-03	38,156	—	$0	38,156	SEC↗
Schwartz Aharon	Director	A Award deriv	2020-02-27	2020-03-03	38,156	—	$0	38,156	SEC↗
STERN STANLEY	Director	A Award deriv	2020-02-27	2020-03-03	12,719	—	$0	12,719	SEC↗
Bruno Anthony D	Director	A Award	2020-02-27	2020-03-03	5,312	—	$0	75,007	SEC↗
Hirsch Stanley	Director	A Award	2020-02-27	2020-03-03	42,493	—	$0	111,858	SEC↗
KAZANCHYAN ANNA	Director	A Award	2020-02-27	2020-03-03	21,246	—	$0	58,744	SEC↗
STERN STANLEY	Director	A Award	2020-02-27	2020-03-03	14,164	—	$0	42,359	SEC↗
Domzalski David	CEO	A Award deriv	2020-02-24	2020-02-24	240,912	—	$0	240,912	SEC↗
Hadar Ilan	CFO & Country Manager	A Award deriv	2020-02-24	2020-02-24	96,365	—	$0	96,365	SEC↗
Harsch Mutya	CLO and General Counsel	A Award deriv	2020-02-24	2020-02-24	96,365	—	$0	96,365	SEC↗
Stuart Iain	Chief Scientific Officer	A Award deriv	2020-02-24	2020-02-24	96,365	—	$0	96,365	SEC↗
Wiley Matthew T.	Chief Commercial Officer	A Award deriv	2020-02-24	2020-02-24	96,365	—	$0	96,365	SEC↗
Domzalski David	CEO	A Award	2020-02-24	2020-02-24	103,248	—	$0	319,323	SEC↗
Hadar Ilan	CFO & Country Manager	A Award	2020-02-24	2020-02-24	41,299	—	$0	130,578	SEC↗
Harsch Mutya	CLO and General Counsel	A Award	2020-02-24	2020-02-24	41,299	—	$0	96,471	SEC↗
Stuart Iain	Chief Scientific Officer	A Award	2020-02-24	2020-02-24	41,299	—	$0	103,636	SEC↗
Wiley Matthew T.	Chief Commercial Officer	A Award	2020-02-24	2020-02-24	41,299	—	$0	112,081	SEC↗
Domzalski David	CEO	F Tax w/h	2019-12-31	2020-01-03	2,751	$3.28	$9.0K	216,075	SEC↗
Harsch Mutya	CLO and General Counsel	F Tax w/h	2019-12-31	2020-01-03	618	$3.28	$2.0K	55,172	SEC↗
Stuart Iain	Chief Scientific Officer	F Tax w/h	2019-12-31	2020-01-03	514	$3.28	$1.7K	62,337	SEC↗
Wiley Matthew T.	Chief Commercial Officer	F Tax w/h	2019-12-31	2020-01-03	2,500	$3.28	$8.2K	70,782	SEC↗
Harsch Mutya	CLO and General Counsel	A Award	2019-11-29	2019-12-03	4,284	$2.16	$9.3K	55,790	SEC↗
Wiley Matthew T.	Chief Commercial Officer	A Award	2019-11-29	2019-12-03	9,842	$2.16	$21.3K	73,282	SEC↗
Domzalski David	CEO	A Award	2019-11-29	2019-12-03	9,842	$2.16	$21.3K	218,826	SEC↗
Hirsch Stanley	Director	M Exercise deriv	2019-11-04	2019-11-05	32,500	—	$0	0	SEC↗
Hirsch Stanley	Director	M Exercise	2019-11-04	2019-11-05	32,500	$0.62	$20.1K	182,500	SEC↗
Hirsch Stanley	Director	M Exercise deriv	2019-10-15	2019-10-17	90,000	—	$0	32,500	SEC↗
Hirsch Stanley	Director	M Exercise	2019-10-15	2019-10-17	90,000	$0.62	$55.8K	150,000	SEC↗
Domzalski David	CEO	F Tax w/h	2019-09-30	2019-10-02	2,256	$3.07	$6.9K	208,984	SEC↗
Harsch Mutya	CLO and General Counsel	F Tax w/h	2019-09-30	2019-10-02	463	$3.07	$1.4K	51,506	SEC↗
Stuart Iain	Chief Scientific Officer	F Tax w/h	2019-09-30	2019-10-02	673	$3.07	$2.1K	62,851	SEC↗
Hadar Ilan	CFO & Country Manager	S Sale	2019-09-10	2019-09-11	34,392	$3.50	$120.4K	89,279	SEC↗
Hadar Ilan	CFO & Country Manager	S Sale	2019-09-09	2019-09-11	9,420	$3.50	$33.0K	123,671	SEC↗
KAZANCHYAN ANNA	Director	S Sale	2019-08-26	2019-08-28	7,049	$3.27	$23.1K	37,498	SEC↗
Hirsch Stanley	Director	M Exercise deriv	2019-08-13	2019-08-14	60,000	—	$0	122,500	SEC↗
Hirsch Stanley	Director	M Exercise	2019-08-13	2019-08-14	60,000	$0.62	$37.2K	60,000	SEC↗
KAZANCHYAN ANNA	Director	S Sale	2019-07-15	2019-07-17	808	$2.31	$1.9K	44,547	SEC↗
Stuart Iain	Chief Scientific Officer	S Sale	2019-07-01	2019-07-03	951	$2.35	$2.2K	63,524	SEC↗
Domzalski David	CEO	S Sale	2019-07-01	2019-07-03	3,355	$2.35	$7.9K	211,240	SEC↗
Harsch Mutya	CLO and General Counsel	S Sale	2019-07-01	2019-07-03	639	$2.35	$1.5K	51,969	SEC↗
KAZANCHYAN ANNA	Director	S Sale	2019-05-20	2019-05-20	10,600	$2.61	$27.7K	45,355	SEC↗
STERN STANLEY	Director	A Award	2019-05-16	2019-07-08	28,195	—	$0	28,195	SEC↗
BARBARI SHARON SURREY	Director	A Award deriv	2019-05-16	2019-05-20	49,412	—	$0	49,412	SEC↗
Bright Rex	Director	A Award deriv	2019-05-16	2019-05-20	49,412	—	$0	49,412	SEC↗
Schwartz Aharon	Director	A Award deriv	2019-05-16	2019-05-20	49,412	—	$0	49,412	SEC↗
Hirsch Stanley	Director	A Award	2019-05-16	2019-05-20	56,391	—	$0	69,365	SEC↗
KAZANCHYAN ANNA	Director	A Award	2019-05-16	2019-05-20	28,195	—	$0	55,955	SEC↗
Bruno Anthony D	Director	A Award	2019-05-16	2019-05-20	28,195	—	$0	69,695	SEC↗
Stuart Iain	Chief Scientific Officer	S Sale	2019-04-01	2019-04-03	1,696	$3.75	$6.4K	64,475	SEC↗
Domzalski David	CEO	S Sale	2019-04-01	2019-04-03	5,096	$3.75	$19.1K	214,595	SEC↗
Harsch Mutya	CLO and General Counsel	S Sale	2019-04-01	2019-04-03	2,519	$3.75	$9.4K	52,608	SEC↗
Wiley Matthew T.	Chief Commercial Officer	P Buy	2019-03-05	2019-03-06	13,440	$3.76	$50.5K	63,440	SEC↗
Domzalski David	CEO	A Award deriv	2019-01-01	2019-01-03	170,993	$3.77	$644.6K	170,993	SEC↗
Harsch Mutya	CLO and General Counsel	A Award deriv	2019-01-01	2019-01-03	70,297	$3.77	$265.0K	70,297	SEC↗
Stuart Iain	Chief Scientific Officer	A Award deriv	2019-01-01	2019-01-03	75,997	$3.77	$286.5K	75,997	SEC↗
Hadar Ilan	CFO & Country Manager	A Award deriv	2019-01-01	2019-01-03	94,996	$3.81	$361.9K	94,996	SEC↗
Domzalski David	CEO	A Award	2019-01-01	2019-01-03	73,282	—	$0	219,691	SEC↗
Harsch Mutya	CLO and General Counsel	A Award	2019-01-01	2019-01-03	30,127	—	$0	55,127	SEC↗
Stuart Iain	Chief Scientific Officer	A Award	2019-01-01	2019-01-03	32,569	—	$0	66,171	SEC↗
Hadar Ilan	CFO & Country Manager	A Award	2019-01-01	2019-01-03	40,712	—	$0	133,091	SEC↗
Wiley Matthew T.	Chief Commercial Officer	A Award deriv	2018-12-03	2018-12-04	100,000	—	$0	100,000	SEC↗
Wiley Matthew T.	Chief Commercial Officer	A Award	2018-12-03	2018-12-04	50,000	—	$0	50,000	SEC↗
Domzalski David	CEO	S Sale	2018-12-03	2018-12-06	68	$4.05	$275	146,409	SEC↗
Schwartz Aharon	Director	P Buy	2018-11-28	2018-12-06	12,200	$3.88	$47.3K	112,200	SEC↗
Schwartz Aharon	Director	P Buy	2018-11-27	2018-12-06	50,000	$3.92	$196.0K	100,000	SEC↗
Schwartz Aharon	Director	P Buy	2018-11-26	2018-12-06	50,000	$3.89	$194.5K	50,000	SEC↗
Howard Alvin D	VP Regulatory	S Sale	2018-11-19	2018-11-20	3,375	$3.90	$13.2K	38,414	SEC↗
Domzalski David	CEO	S Sale	2018-11-19	2018-11-20	5,036	$3.90	$19.6K	146,477	SEC↗
Domzalski David	CEO	S Sale	2018-11-08	2018-11-13	2,062	$4.58	$9.4K	151,513	SEC↗
Stuart Iain	SVP R&D	S Sale	2018-11-08	2018-11-13	683	$4.58	$3.1K	33,602	SEC↗
Domzalski David	CEO	S Sale	2018-10-01	2018-10-02	601	$5.81	$3.5K	153,575	SEC↗
Elliott Russell P.	VP Drug Development	S Sale	2018-10-01	2018-10-02	142	$5.81	$825	12,442	SEC↗
Howard Alvin D	VP Regulatory	S Sale	2018-10-01	2018-10-02	234	$5.81	$1.4K	41,789	SEC↗
Domzalski David	CEO	S Sale	2018-09-04	2018-09-06	67	$5.67	$380	154,176	SEC↗
Stuart Iain	SVP R&D	S Sale	2018-08-08	2018-08-09	2,715	$5.68	$15.4K	34,285	SEC↗
Domzalski David	CEO	S Sale	2018-08-08	2018-08-09	8,238	$5.68	$46.8K	154,243	SEC↗
Hirsch Stanley	Director	M Exercise deriv	2018-07-13	2018-07-13	1,616	—	$0	0	SEC↗
Hirsch Stanley	Director	M Exercise	2018-07-13	2018-07-13	1,616	—	$0	12,974	SEC↗
Elliott Russell P.	VP Drug Development	S Sale	2018-07-02	2018-07-03	142	$5.10	$724	12,584	SEC↗
Howard Alvin D	VP Regulatory	S Sale	2018-07-02	2018-07-03	234	$5.10	$1.2K	42,023	SEC↗
Domzalski David	CEO	S Sale	2018-07-02	2018-07-03	602	$5.10	$3.1K	162,481	SEC↗
Domzalski David	CEO	S Sale	2018-06-01	2018-06-04	67	$5.26	$352	163,083	SEC↗
Hirsch Stanley	Director	X Exercise deriv	2018-05-13	2018-05-31	6,224	—	$0	0	SEC↗
Hirsch Stanley	Director	X Exercise	2018-05-13	2018-05-31	6,224	$5.04	$31.4K	12,672	SEC↗
Hirsch Stanley	Director	S Sale	2018-05-13	2018-05-31	6,164	$5.09	$31.4K	6,508	SEC↗
Megiddo Dalia	Director	A Award deriv	2018-05-08	2018-05-10	24,883	—	$0	24,883	SEC↗
Schwartz Aharon	Director	A Award deriv	2018-05-08	2018-05-10	24,883	—	$0	24,883	SEC↗
STERN STANLEY	Director	A Award deriv	2018-05-08	2018-05-10	24,947	—	$0	24,947	SEC↗
Domzalski David	CEO	A Award deriv	2018-05-08	2018-05-10	70,187	—	$0	70,187	SEC↗
RIGEL DARRELL S	Director	A Award deriv	2018-05-08	2018-05-10	24,947	—	$0	24,947	SEC↗
Hirsch Stanley	Director	A Award deriv	2018-05-08	2018-05-10	49,766	—	$0	49,766	SEC↗
Bright Rex	Director	A Award deriv	2018-05-08	2018-05-10	24,947	—	$0	24,947	SEC↗
Domzalski David	CEO	A Award	2018-05-08	2018-05-10	23,396	—	$0	163,150	SEC↗
KAZANCHYAN ANNA	Director	A Award	2018-05-08	2018-05-10	14,829	—	$0	27,760	SEC↗
Domzalski David	CEO	S Sale	2018-04-02	2018-04-04	602	$5.08	$3.1K	139,754	SEC↗
Elliott Russell P.	VP Drug Development	S Sale	2018-04-02	2018-04-04	142	$5.08	$721	12,726	SEC↗
Howard Alvin D	VP Regulatory	S Sale	2018-04-02	2018-04-04	234	$5.08	$1.2K	42,257	SEC↗
Elliott Russell P.	VP Drug Development	S Sale	2018-03-02	2018-03-06	817	$6.14	$5.0K	12,868	SEC↗
Domzalski David	CEO	S Sale	2018-03-01	2018-03-05	66	$5.95	$393	140,356	SEC↗
Elliott Russell P.	VP Drug Development	A Award deriv	2018-02-27	2018-02-28	26,250	$6.35	$166.7K	26,250	SEC↗
Harsch Mutya	General Counsel and SVP	A Award deriv	2018-02-27	2018-02-28	50,000	$6.35	$317.5K	50,000	SEC↗
Hazot Yohan	VP Pharmaceutical Developmen	A Award deriv	2018-02-27	2018-02-28	15,000	$6.40	$96.0K	15,000	SEC↗
Howard Alvin D	VP Regulatory	A Award deriv	2018-02-27	2018-02-28	22,500	$6.35	$142.9K	22,500	SEC↗
Stuart Iain	SVP R&D	A Award deriv	2018-02-27	2018-02-28	30,000	$6.35	$190.5K	30,000	SEC↗
Hadar Ilan	CFO & Country Manager	A Award deriv	2018-02-27	2018-02-28	35,093	$6.40	$224.6K	35,093	SEC↗
Shirvan Mitchell	VP Innovation & Discovery	A Award deriv	2018-02-27	2018-02-28	15,000	$6.40	$96.0K	15,000	SEC↗
Schuz David	VP Intellectual Property	A Award deriv	2018-02-27	2018-02-28	15,000	$6.40	$96.0K	15,000	SEC↗
Elliott Russell P.	VP Drug Development	A Award	2018-02-27	2018-02-28	8,750	—	$0	13,685	SEC↗
Harsch Mutya	General Counsel and SVP	A Award	2018-02-27	2018-02-28	25,000	—	$0	25,000	SEC↗
Hazot Yohan	VP Pharmaceutical Developmen	A Award	2018-02-27	2018-02-28	5,000	—	$0	32,300	SEC↗
Howard Alvin D	VP Regulatory	A Award	2018-02-27	2018-02-28	7,500	—	$0	42,491	SEC↗
Stuart Iain	SVP R&D	A Award	2018-02-27	2018-02-28	10,000	—	$0	37,000	SEC↗
Hadar Ilan	CFO & Country Manager	A Award	2018-02-27	2018-02-28	11,698	—	$0	92,379	SEC↗
Shirvan Mitchell	VP Innovation & Discovery	A Award	2018-02-27	2018-02-28	5,000	—	$0	24,980	SEC↗
Schuz David	VP Intellectual Property	A Award	2018-02-27	2018-02-28	5,000	—	$0	24,980	SEC↗
Eini Meir	Other	M Exercise deriv	2018-01-15	2018-01-18	1,125	—	$0	4,500	SEC↗
Hazot Yohan	VP Pharmaceutical Developmen	M Exercise deriv	2018-01-15	2018-01-24	562	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	M Exercise deriv	2018-01-15	2018-01-24	562	—	$0	0	SEC↗
Shirvan Mitchell	VP Innovation & Discovery	M Exercise deriv	2018-01-15	2018-01-24	562	—	$0	0	SEC↗
Schuz David	VP IP	M Exercise deriv	2018-01-15	2018-01-24	562	—	$0	0	SEC↗
Eini Meir	Other	M Exercise	2018-01-15	2018-01-18	1,125	—	$0	17,396	SEC↗
Hazot Yohan	VP Pharmaceutical Developmen	M Exercise	2018-01-15	2018-01-24	562	—	$0	27,300	SEC↗
Hadar Ilan	CFO & Country Manager	M Exercise	2018-01-15	2018-01-24	562	—	$0	80,681	SEC↗
Shirvan Mitchell	VP Innovation & Discovery	M Exercise	2018-01-15	2018-01-24	562	—	$0	19,980	SEC↗
Schuz David	VP IP	M Exercise	2018-01-15	2018-01-24	562	—	$0	19,980	SEC↗
Eini Meir	Other	S Sale	2018-01-11	2018-01-18	5,000	$6.33	$31.6K	2,717,781	SEC↗
Eini Meir	Other	S Sale	2018-01-10	2018-01-18	5,000	$6.05	$30.3K	2,722,781	SEC↗
Eini Meir	Other	S Sale	2018-01-09	2018-01-18	5,000	$6.10	$30.5K	2,727,781	SEC↗
Eini Meir	Other	S Sale	2018-01-08	2018-01-18	5,000	$6.17	$30.9K	2,732,781	SEC↗
Eini Meir	Other	S Sale	2018-01-05	2018-01-18	5,000	$6.58	$32.9K	2,737,781	SEC↗
Eini Meir	Other	S Sale	2018-01-04	2018-01-18	5,000	$6.68	$33.4K	2,742,781	SEC↗
Eini Meir	Other	S Sale	2018-01-03	2018-01-18	5,000	$6.26	$31.3K	2,747,781	SEC↗
Eini Meir	Other	S Sale	2018-01-02	2018-01-18	5,000	$6.18	$30.9K	2,752,781	SEC↗
Howard Alvin D	VP Regulatory	F Tax w/h	2018-01-02	2018-01-24	924	$5.98	$5.5K	34,991	SEC↗
Domzalski David	CEO	F Tax w/h	2018-01-02	2018-01-24	2,397	$5.98	$14.3K	140,422	SEC↗
Elliott Russell P.	VP Drug Development	F Tax w/h	2018-01-02	2018-01-24	555	$5.98	$3.3K	4,935	SEC↗
Eini Meir	Other	M Exercise deriv	2018-01-01	2018-01-18	5,032	—	$0	15,098	SEC↗
Hazot Yohan	VP Pharmaceutical Developmen	M Exercise deriv	2018-01-01	2018-01-24	4,575	—	$0	0	SEC↗
Howard Alvin D	VP Regulatory	M Exercise deriv	2018-01-01	2018-01-24	2,288	—	$0	0	SEC↗
Domzalski David	CEO	M Exercise deriv	2018-01-01	2018-01-24	5,948	—	$0	0	SEC↗
Elliott Russell P.	VP Drug Development	M Exercise deriv	2018-01-01	2018-01-24	1,372	—	$0	0	SEC↗
Hadar Ilan	CFO & Country Manager	M Exercise deriv	2018-01-01	2018-01-24	5,032	—	$0	0	SEC↗
Shirvan Mitchell	VP Innovation & Discovery	M Exercise deriv	2018-01-01	2018-01-24	2,745	—	$0	0	SEC↗
Schuz David	VP IP	M Exercise deriv	2018-01-01	2018-01-24	2,745	—	$0	0	SEC↗
Eini Meir	Other	M Exercise	2018-01-01	2018-01-18	5,032	—	$0	16,271	SEC↗
Hazot Yohan	VP Pharmaceutical Developmen	M Exercise	2018-01-01	2018-01-24	4,575	—	$0	27,300	SEC↗
Howard Alvin D	VP Regulatory	M Exercise	2018-01-01	2018-01-24	2,288	—	$0	35,915	SEC↗
Domzalski David	CEO	M Exercise	2018-01-01	2018-01-24	5,948	—	$0	142,819	SEC↗
Elliott Russell P.	VP Drug Development	M Exercise	2018-01-01	2018-01-24	1,372	—	$0	5,490	SEC↗
Hadar Ilan	CFO & Country Manager	M Exercise	2018-01-01	2018-01-24	5,032	—	$0	80,681	SEC↗
Shirvan Mitchell	VP Innovation & Discovery	M Exercise	2018-01-01	2018-01-24	2,745	—	$0	19,980	SEC↗
Schuz David	VP IP	M Exercise	2018-01-01	2018-01-24	2,745	—	$0	19,980	SEC↗